Thermo Fisher Scientific Inc. $TMO Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 31.9% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 526,587 shares of the medical research company’s stock after selling 246,822 shares during the period. Ensign Peak Advisors Inc’s holdings in Thermo Fisher Scientific were worth $213,510,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC grew its position in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after buying an additional 988 shares in the last quarter. Revolve Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares in the last quarter. J.W. Cole Advisors Inc. raised its position in shares of Thermo Fisher Scientific by 113.5% during the 1st quarter. J.W. Cole Advisors Inc. now owns 3,828 shares of the medical research company’s stock valued at $1,905,000 after acquiring an additional 2,035 shares in the last quarter. Proficio Capital Partners LLC boosted its holdings in Thermo Fisher Scientific by 4.0% in the first quarter. Proficio Capital Partners LLC now owns 1,525 shares of the medical research company’s stock worth $759,000 after purchasing an additional 59 shares during the period. Finally, Oak Thistle LLC bought a new stake in Thermo Fisher Scientific during the first quarter valued at $4,248,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insiders Place Their Bets

In other news, VP Lisa P. Britt sold 10,225 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the sale, the vice president directly owned 14,145 shares of the company’s stock, valued at $8,085,564.90. The trade was a 41.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the completion of the transaction, the executive vice president owned 21,152 shares of the company’s stock, valued at $12,144,420.80. This trade represents a 1.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 51,845 shares of company stock worth $28,956,952. Corporate insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TMO. UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research report on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, October 14th. Leerink Partners boosted their price target on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. Finally, TD Cowen boosted their target price on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Nineteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $601.65.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $573.39 on Thursday. The stock’s 50 day moving average price is $533.28 and its 200 day moving average price is $471.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The stock has a market cap of $215.43 billion, a price-to-earnings ratio of 33.12, a PEG ratio of 3.27 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.Thermo Fisher Scientific’s revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has approved a share buyback program on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is 9.94%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.